HBG1 and Schnyder corneal dystrophy: In this study, we analyzed the effects of CRISPR-Cas9-mediated GE in a side-by-side comparison between HD and SCD patient-derived HSPCs to evaluate the efficacy and safety of a gene therapy approach targeting the HBG1/2 promoters in clinically relevant conditions.